Payment overview · 2025
General Payments
$561.90
13 reported records · 9 companies
Healthcare provider profile · identity verified
Atef Mousa, DO
Allopathic & Osteopathic Physicians|Internal Medicine · JERSEY CITY, NJ · NPI 1891006565
Verified facts
What the public records show
CMS Open Payments records show Atef Mousa, DO received $561.90 in general payments during 2025 across 13 reported records.
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $244.97 | 43.6% | 4 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $124.67 | 22.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.19 | 9.5% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $28.69 | 5.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.61 | 4.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.67 | 4.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.06 | 4.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.20 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.84 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.90 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $244.97 | 4 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $124.67 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $53.28 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
15 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 33 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1055 | 275 |
| Eliquis | Apixaban | 783 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 673 | 179 |
| Gabapentin | Gabapentin | 585 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 547 | 154 |
| Furosemide | Furosemide | 488 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 100 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 406 | 132 |
| Potassium Chloride | Potassium Chloride | 345 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 322 | 83 |
| Lisinopril | Lisinopril | 308 | 97 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 302 | 62 |
| Famotidine | Famotidine | 296 | 67 |
| Losartan Potassium | Losartan Potassium | 290 | 76 |
| Carvedilol | Carvedilol | 289 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 269 | 90 |
| Metformin Hcl | Metformin Hcl | 261 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 241 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 241 | 79 |
| Levetiracetam | Levetiracetam | 221 | 51 |
| Xarelto | Rivaroxaban | 211 | 40 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 205 | 98 |
| Sucralfate | Sucralfate | 183 | 42 |
| Humalog | Insulin Lispro | 182 | 54 |
| Baclofen | Baclofen | 181 | 48 |
| Spironolactone | Spironolactone | 168 | 60 |
| Donepezil Hcl | Donepezil Hcl | 163 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 163 | 59 |
| Memantine Hcl | Memantine Hcl | 150 | 28 |
| Omeprazole | Omeprazole | 139 | 33 |
| Jardiance | Empagliflozin | 138 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 39 |
| Alendronate Sodium | Alendronate Sodium | 131 | 44 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 130 | 36 |
| Midodrine Hcl | Midodrine Hcl | 130 | 27 |
| Trazodone Hcl | Trazodone Hcl | 128 | 42 |
| Januvia | Sitagliptin Phosphate | 123 | 18 |
| Monoject Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 123 | 33 |
| Entresto | Sacubitril/Valsartan | 122 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 120 | 29 |
| Clonidine Hcl | Clonidine Hcl | 117 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 117 | 21 |
| Lorazepam | Lorazepam | 108 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 61 |
| Allopurinol | Allopurinol | 105 | 31 |
| Glucagon Emergency Kit | Glucagon | 104 | 45 |
| Humulin R | Insulin Regular, Human | 104 | 30 |
| Mirtazapine | Mirtazapine | 104 | 21 |
| Tramadol Hcl | Tramadol Hcl | 101 | 39 |
| Sertraline Hcl | Sertraline Hcl | 96 | 25 |
| Olanzapine | Olanzapine | 92 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 89 | 38 |
| Finasteride | Finasteride | 89 | 24 |
| Levofloxacin | Levofloxacin | 87 | 75 |
| Latanoprost | Latanoprost | 86 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 63 |
| Sodium Chloride | 0.9 % Sodium Chloride | 81 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 24 |
| Atorvaliq | Atorvastatin Calcium | 79 | 12 |
| Azithromycin | Azithromycin | 79 | 50 |
| Simvastatin | Simvastatin | 79 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 29 |
| Alprazolam | Alprazolam | 76 | 22 |
| Enulose | Lactulose | 76 | 34 |
| Megestrol Acetate | Megestrol Acetate | 76 | 29 |
| Linzess | Linaclotide | 73 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 31 |
| Montelukast Sodium | Montelukast Sodium | 72 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 25 |
| Morphine Sulfate Er | Morphine Sulfate | 70 | 12 |
| Farxiga | Dapagliflozin Propanediol | 69 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 58 |
| Buspirone Hcl | Buspirone Hcl | 67 | 17 |
| Glipizide | Glipizide | 67 | 21 |
| Enoxaparin Sodium | Enoxaparin Sodium | 65 | 23 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 63 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 17 |
| Methylprednisolone | Methylprednisolone | 61 | 47 |
| Propranolol Hcl | Propranolol Hcl | 60 | 11 |
| Prednisone | Prednisone | 58 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 53 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 25 |
| Bumetanide | Bumetanide | 52 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 41 |
| Cefepime Hcl | Cefepime Hcl | 51 | 13 |
| Sevelamer Hcl | Sevelamer Hcl | 51 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 49 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 12 |
| Digoxin | Digoxin | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Cephalexin | Cephalexin | 47 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 11 |
| Fentanyl | Fentanyl | 47 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 47 | 12 |
| Metronidazole | Metronidazole | 47 | 38 |
| Valsartan | Valsartan | 47 | 14 |
| Nystatin | Nystatin | 45 | 29 |
| Atenolol | Atenolol | 44 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 34 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 43 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 43 | 11 |
| Pregabalin | Pregabalin | 43 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 25 |
| Diltiazem Hcl | Diltiazem Hcl | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Novolin R | Insulin Regular, Human | 41 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 41 | 11 |
| Dorzolamide Hcl | Dorzolamide Hcl | 40 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 40 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 14 |
| Methadone Hcl | Methadone Hcl | 38 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 38 | 15 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 37 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 23 |
| Ertapenem | Ertapenem Sodium | 36 | 17 |
| Celecoxib | Celecoxib | 35 | 16 |
| Methocarbamol | Methocarbamol | 35 | 16 |
| Morphine Sulfate | Morphine Sulfate | 35 | suppressed |
| Movantik | Naloxegol Oxalate | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 21 |
| Lumigan | Bimatoprost | 34 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Calcium Acetate | Calcium Acetate | 32 | 12 |
| Lactulose | Lactulose | 32 | 22 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | 14 |
| Brilinta | Ticagrelor | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 19 |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 13 |
| Acetazolamide | Acetazolamide | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Insulin Lispro | Insulin Lispro | 27 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | 13 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 27 | 14 |
| Vancomycin Hcl | Vancomycin Hcl | 27 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 16 |
| Mupirocin | Mupirocin | 25 | 18 |
| Estradiol | Estradiol | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Qbrelis | Lisinopril | 24 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | 12 |
| Folic Acid | Folic Acid | 23 | suppressed |
| Norliqva | Amlodipine Besylate | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Auryxia | Ferric Citrate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Daptomycin | Daptomycin | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | 12 |
| Heparin Sodium | Heparin Sodium,porcine | 20 | suppressed |
| Linezolid | Linezolid | 20 | 18 |
| Lovenox | Enoxaparin Sodium | 20 | suppressed |
| Permethrin | Permethrin | 20 | 13 |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Tacrolimus | Tacrolimus | 20 | 13 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 19 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Valproic Acid | Valproic Acid | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 17 | suppressed |
| Difluprednate | Difluprednate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 15 | 12 |
| Cefdinir | Cefdinir | 15 | 15 |
| Diazepam | Diazepam | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 13 |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Tavaborole | Tavaborole | 14 | 12 |
| Acetic Acid | Acetic Acid | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 13 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | 11 |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Glucagen | Glucagon | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Scopolamine | Scopolamine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $561.90 · 13 records | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | AUSTEDO XR, FARXIGA, Fetroja, JARDIANCE, LifeVest, Prolastin-C Liquid, REXULTI, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error